Quick Heal Technologies LtdQ2 FY22IT - Software

Quick Heal Technologies Ltd

Q2 FY22 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Enterprise business is growing rapidly (50% YoY growth in Q1 FY23) and currently forms about one-third of total revenue, with a target to reach a 50-50 mix with retail in the next two years.
→Retail (consumer) segment is relatively flat, with growth in India at about 1%, but the company maintains the highest market share (~30%).
→New products in Zero Trust, Data Privacy, EDR, and XDR are in beta/pilot stages; revenue from these is expected to start flowing from H1 FY24 onward.
→Future revenue growth will be driven by enterprise sales, with ongoing investment in R&D and marketing.
→Management’s vision targets reasonable revenue growth, focusing on building product-market fit for emerging technologies and expanding enterprise clientele, including larger organizations.
→Awareness and demand generation, especially in enterprise, will influence future volume and sales growth.
→Overall, expect modest retail growth, strong enterprise growth, and gradual revenue ramp-up from new cybersecurity products over the next 3-5 years.

Category 3

→The company aims for a balanced revenue mix of 50-50 between retail and enterprise segments in the next two years, with enterprise expected to grow faster (around 11% globally).
→Current revenue growth is modest, with retail segment flat at about 1% growth in India, but enterprise business grew ~50% YoY in Q1 FY23.
→Significant investment in R&D (around ₹150 crore over two years) targets future products like Zero Trust and Data Privacy, expected to generate revenues starting H1 FY24.
→New product launches (e.g., Zero Trust User Access) have started onboarding customers, with revenue traction expected over 4-6 quarters.
→Operating profits are impacted by increased R&D and sales & marketing expenses as part of growth investments.
→The management expects reasonable revenue growth with continued cost optimization aiming for better profitability over the medium term.
→EPS improvement has been supported by buybacks; organic growth in earnings is expected to pick up with new products gaining market acceptance.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Quick Heal Technologies Ltd and 1,400+ other companies.

→There is no mention of any current or future fundraising through debt or equity in the provided pages.
→The company plans to use approximately ₹200 crore available in its books (post buyback and dividend) for organic and inorganic growth opportunities.
→Investments are mainly focused on R&D and product development rather than raising external capital.
→The management emphasizes internal funding for growth, with ₹150 crore already invested in R&D over the last two years.
→No plans for external equity or debt fundraising were discussed during the Q&A or management commentary.

→The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited.
→Management emphasizes focus on product launches, particularly in enterprise security, with growing demand for new products like Zero Trust and Data Privacy solutions.
→They highlighted increasing traction and onboarding early customers for these new products, suggesting a growing pipeline.
→No specific quantitative details regarding order book size or pending orders were disclosed.
→Emphasis is on building product-market fit over 4 to 6 quarters, with revenues expected from H1 FY24.
→Growth in enterprise segment revenue by around 50% YoY in Q1 FY23 indicates a robust order pipeline but no direct order book figures provided.
→Overall, no concrete data on pending or confirmed orders is shared in the transcript.

→The company’s major investment focus is on R&D rather than traditional Capex, which is described as very limited or insignificant in the larger scheme of things.
→Recent R&D investments (close to ₹150 crores in last two years) target improving existing products and developing new ones, especially in zero trust, data privacy, endpoint security, and enterprise products.
→Strategic investment includes a sizable stake in an Israeli entity specializing in future technology (endpoint security), which is progressing well in product development.
→The company plans to use approximately ₹200 crore available after buyback and dividend for organic and inorganic growth opportunities.
→They have also onboarded a top global consultancy to help shape long-term strategic growth.
→No major standalone Capex plans were mentioned, with emphasis placed on investment in product development and marketing to capture market growth.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

1Quick Heal Technologies Ltd

Rev 3Mar 3

See full IT - Software sector rankings

Want more stocks like Quick Heal Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.